EHA Library - The official digital education library of European Hematology Association (EHA)

TREATMENT OUTCOME OF MONOMORPHIC EPITHELIOTROPIC INTESTINAL T-CELL LYMPHOMA (MEITL): EXPERIENCE FROM AN ASIAN CANCER CENTER
Author(s):
Meng-Ta Sung
,
Meng-Ta Sung
Affiliations:
Department of Hematology and Medical Oncology,Koo Foundation Sun Yat-Sen Cancer Center,Taipei City,Taiwan, Province of China
Ming-Yuan Lee
,
Ming-Yuan Lee
Affiliations:
Department of Pathology and Laboratory Medicine,Koo Foundation Sun Yat-Sen Cancer Center,Taipei City,Taiwan, Province of China
Mau-Ching Wu
,
Mau-Ching Wu
Affiliations:
Department of Hematology and Medical Oncology,Koo Foundation Sun Yat-Sen Cancer Center,Taipei City,Taiwan, Province of China
Tran-Der Tan
Tran-Der Tan
Affiliations:
Department of Hematology and Medical Oncology,Koo Foundation Sun Yat-Sen Cancer Center,Taipei City,Taiwan, Province of China
(Abstract release date: 05/18/17) EHA Library. Sung M. 05/18/17; 182451; PB1737
Mr. Meng-Ta Sung
Mr. Meng-Ta Sung
Contributions
PDF Abstract
Abstract

Abstract: PB1737

Type: Publication Only

Background
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), previously type II enteropathy-associated T-cell lymphoma(EATL), primarily occurred in Asian countries. It is refractory to chemotherapy and the prognosis is poor. Intensive chemotherapy has been proposed to improve treatment outcome.

Aims
We examined the treatment outcome of MEITL in our institution.

Methods
We retrospectively searched our institutional database from 1996 to 2014 for intestinal T-cell lymphoma. Medical records were reviewed and the patients were classified on the basis of WHO-2016 classification. Patient’s characteristics, treatment modalities, response and survival were collected and analyzed.

Results
Ten patients with intestinal T-cell lymphoma were identified. One patient had enteropathy-associated T-cell lymphoma (EATL) presenting with celiac sprue. Five patients had intestinal T-cell lymphoma, NOS. Four patients were diagnosed with monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).

For patients with MEITL, median overall survival was 7.9 months (4.2-15.0 months). Median age was 46 years of age. Bowel perforation was the initial presentation in 3 patients (3/4, 75%).
One patient was treated with chemotherapy with CHOP regimen, while another patient underwent surgery alone. The remaining two patients (2/4, 50%) received surgery followed by chemotherapy (one with CHOP, the other with BFM-90 protocol). Only one patient (1/4, 25%) entered complete response. Of concern, the unique patient achieved complete response received surgery followed by chemotherapy with Berlin-Frankfurt-Munster(BFM)-90 protocol. Remission duration was 10.3 months. He passed away 15.0 months after remission because of relapsed lymphoma.

Conclusion
Though the prognosis of MEITL is poor, operation followed by high dose chemotherapy such as BFM-90 protocol may have better treatment response, response duration and survival. It deserves further investigation.

Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical

Abstract: PB1737

Type: Publication Only

Background
Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), previously type II enteropathy-associated T-cell lymphoma(EATL), primarily occurred in Asian countries. It is refractory to chemotherapy and the prognosis is poor. Intensive chemotherapy has been proposed to improve treatment outcome.

Aims
We examined the treatment outcome of MEITL in our institution.

Methods
We retrospectively searched our institutional database from 1996 to 2014 for intestinal T-cell lymphoma. Medical records were reviewed and the patients were classified on the basis of WHO-2016 classification. Patient’s characteristics, treatment modalities, response and survival were collected and analyzed.

Results
Ten patients with intestinal T-cell lymphoma were identified. One patient had enteropathy-associated T-cell lymphoma (EATL) presenting with celiac sprue. Five patients had intestinal T-cell lymphoma, NOS. Four patients were diagnosed with monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL).

For patients with MEITL, median overall survival was 7.9 months (4.2-15.0 months). Median age was 46 years of age. Bowel perforation was the initial presentation in 3 patients (3/4, 75%).
One patient was treated with chemotherapy with CHOP regimen, while another patient underwent surgery alone. The remaining two patients (2/4, 50%) received surgery followed by chemotherapy (one with CHOP, the other with BFM-90 protocol). Only one patient (1/4, 25%) entered complete response. Of concern, the unique patient achieved complete response received surgery followed by chemotherapy with Berlin-Frankfurt-Munster(BFM)-90 protocol. Remission duration was 10.3 months. He passed away 15.0 months after remission because of relapsed lymphoma.

Conclusion
Though the prognosis of MEITL is poor, operation followed by high dose chemotherapy such as BFM-90 protocol may have better treatment response, response duration and survival. It deserves further investigation.

Session topic: 20. Aggressive Non-Hodgkin lymphoma - Clinical

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies